- 20% growth in CGuard™ revenue Year-over-Year -
- C-Guardian FDA IDE Trial Completes First European Enrollment -
Read more at globenewswire.comAll information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
- 20% growth in CGuard™ revenue Year-over-Year -
- C-Guardian FDA IDE Trial Completes First European Enrollment -
Read more at globenewswire.com| Symbol | Last | Chg | %Chg |
|---|---|---|---|
| NSPR | 1.6500 | -0.1000 | -5.71% |
| Inspiremd Inc | |||